Gainor Danielle L, Marchiano Emily, Bellile Emily, Spector Matthew E, Taylor Jeremy M G, Wolf Gregory T, Hogikyan Norman D, Prince Mark E, Bradford Carol R, Eisbruch Avraham, Worden Francis, Shuman Andrew G
1 Department of Otolaryngology-Head and Neck Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA.
2 Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Otolaryngol Head Neck Surg. 2017 Oct;157(4):625-630. doi: 10.1177/0194599817711374. Epub 2017 Jun 13.
Objective Emerging data have demonstrated suboptimal outcomes among patients with stage II larynx cancer. Our objective is to report survival outcomes for T2N0M0 larynx cancer and to determine the cause-specific survival. Study Design Case series with planned data collection. Setting Tertiary academic center. Subjects Adults with T2N0M0 squamous cell carcinoma of the larynx treated with curative intent. Methods A head and neck cancer epidemiology database was queried for eligible subjects from 2003 to 2014. Data were extracted from the electronic medical record and research database, and survival analyses were performed. Results Thirty-four patients with previously untreated stage II larynx cancer were identified (median follow-up 48 months). Patients included 27 males and 7 females with a mean age of 59 years. The majority of tumors arose from the glottis (59%). Of the cohort, 12% were treated with surgery, 65% radiation therapy, and 24% chemoradiation therapy. The estimated 2-year overall survival was 81%, (95% confidence interval [CI], 59%-92%), disease-specific survival was 91% (95% CI, 69%-98%), and recurrence-free survival was 84% (95% CI, 65%-93%). Four of 5 patients with persistent or recurrent disease posttreatment were successfully salvaged with total laryngectomy with 100% locoregional control. There were 11 mortalities (2 disease related, 2 due to metachronous primaries, 3 treatment related, and 4 from other/unknown causes). Conclusion Stage II laryngeal cancer has suboptimal survival outcomes. This appears to be a reflection of medical comorbidities, propensity for metachronous primaries, and the sequelae of late treatment effects rather than poor locoregional control.
目的 新出现的数据显示,II期喉癌患者的治疗效果欠佳。我们的目的是报告T2N0M0喉癌的生存结果,并确定病因特异性生存率。研究设计 带有计划数据收集的病例系列研究。研究地点 三级学术中心。研究对象 接受根治性治疗的T2N0M0喉鳞状细胞癌成年患者。方法 检索头颈癌流行病学数据库,以获取2003年至2014年符合条件的研究对象。从电子病历和研究数据库中提取数据,并进行生存分析。结果 确定了34例未经治疗的II期喉癌患者(中位随访时间48个月)。患者包括27名男性和7名女性,平均年龄59岁。大多数肿瘤起源于声门(59%)。在该队列中,12%接受手术治疗,65%接受放射治疗,24%接受放化疗。估计2年总生存率为81%(95%置信区间[CI],59%-92%),疾病特异性生存率为91%(95%CI,69%-98%),无复发生存率为84%(95%CI,65%-93%)。5例治疗后疾病持续或复发的患者中有4例通过全喉切除术成功挽救,局部区域控制率为100%。有11例死亡(2例与疾病相关,2例由于异时性原发肿瘤,3例与治疗相关,4例原因不明)。结论 II期喉癌的生存结果欠佳。这似乎反映了合并症、异时性原发肿瘤的倾向以及晚期治疗效应的后遗症,而非局部区域控制不佳。